Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06251973
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:54.081378+00:00
Published At
2025-12-02T00:00:00+00:00
Record Updated At
2025-12-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Metastatic Esophageal Carcinoma", "Advanced Unresectable Gastric Adenocarcinoma", "Metastatic Gastric Cancer", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Esophageal Cancer", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastric Carcinoma", "Unresectable Esophageal Cancer", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-02"
protocolSection.identificationModule.nctId
"NCT06251973"
protocolSection.identificationModule.officialTitle
"A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Metastatic Esophageal Carcinoma (protocolSection.conditionsModule.conditions)
  • Advanced Unresectable Gastric Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Gastric Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Gastric Carcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Unresectable Esophageal Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Gastric Carcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Gastric Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Unresectable Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.